Bibliography
1. Tsourdi E, Rachner TD, Rauner M, Hamann C, Hofbauer LC. Denosumab for bone diseases: Translating bone biology into targeted therapy. Eur J Endocrinol. 2011;165(6):833–40.
2. Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–65.
3. Ferrari S, Adachi JD, Lippuner K, Zapalowski C, Miller PD, Reginster JY, et al. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. Osteoporos Int. 2015;26(12):2763–71.
4. Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: A randomized second extension to the HORIZON-pivotal fracture trial (PFT). J Bone Miner Res. 2015;30(5):934–44.
5. Popp AW, Varathan N, Buffat H, Senn C, Perrelet R, Lippuner K. Bone Mineral Density Changes After 1 Year of Denosumab Discontinuation in Postmenopausal Women with Long-Term Denosumab Treatment for Osteoporosis. Calcif Tissue Int. 2018;103(1):50–4.
6. Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases. J Bone Miner Res. 2017;32(6):1291–6.
7. Gonzalez-Rodriguez E, Aubry-Rozier B, Stoll D, Zaman K, Lamy O. Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors. Breast Cancer Res Treat. 2020;179(1):153–9.
8. Lamy O, Gonzalez-Rodriguez E, Stoll D, Hans D, Aubry-Rozier B. Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J Clin Endocrinol Metab. 2017;102(2):354–8.
9. Tripto-Shkolnik L, Rouach V, Marcus Y, Rotman-Pikielny P, Benbassat C, Vered I. Vertebral Fractures Following Denosumab Discontinuation in Patients with Prolonged Exposure to Bisphosphonates. Calcif Tissue Int. 2018;103(1):44–9.
10. Sosa Henríquez M, Gómez de Tejada Romero MJ, Escudero-Socorro M, Torregrosa Suau O. Hip fractures following denosumab discontinuation: three clinical cases reports. J R Soc Med. 2019;112(11):472–5.
11. Niimi R, Kono T, Nishihara A, Hasegawa M, Kono T, Sudo A. Second rebound-associated vertebral fractures after denosumab discontinuation. Arch Osteoporos. 2020;15(1):10–2.
12. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8(9):1137–48.
13. World Medical Association. World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013;310(20):2013–6.
14. Fernández Fernández E, Benavent Núñez D, Bonilla Hernán G, Monjo Henry I, García Carazo S, Bernad Pineda M, et al. Fracturas vertebrales múltiples tras la suspensión de tratamiento con denosumab: serie de diez casos. Reumatol Clínica. 2019;
15. Florez H, Ramírez J, Monegal A, Guañabens N, Peris P. Spontaneous vertebral fractures after denosumab discontinuation: A case collection and review of the literature. Semin Arthritis Rheum. 2019;49(2):197–203.
16. Tripto-Shkolnik L, Fund N, Rouach V, Chodick G, Shalev V, Goldshtein I. Fracture incidence after denosumab discontinuation: Real-world data from a large healthcare provider. Bone. 2020;130:115150.
17. Iranikhah M, Deas C, Murphy P, Freeman MK. Effects of Denosumab After Treatment Discontinuation : A Review of the Literature. Consult Pharm. 2018;33(3):142–51.
18. Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guañabens N, et al. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone. 2017;105:11–7.
19. Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, Lamy O. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int. 2016;27(5):1923–5.
20. Anastasilakis AD, Makras P. Multiple clinical vertebral fractures following denosumab discontinuation. Osteoporos Int. 2016;27(5):1929–30.
21. Rao SD, Qiu S, Dhaliwal R, Bhadada SK. Letter to the editor: Severe rebound-associated vertebral fractures after denosumab discontinuation. J Clin Endocrinol Metab. 2017;102(6):2111.
22. Tripto-Shkolnik L, Rouach V, Marcus Y, Rotman-Pikielny P, Benbassat C, Vered I. Vertebral Fractures Following Denosumab Discontinuation in Patients with Prolonged Exposure to Bisphosphonates. Calcif Tissue Int. 2018;103(1):44–9.
23. Niimi R, Kono T, Nishihara A, Hasegawa M, Kono T, Sudo A. Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis. Osteoporos Int. 2018;29(3):769–72.
24. Díez-Pérez A.The debate over the FRAX scale. Rev Osteoporos Metab Miner. 2010;2(1):5–6.
25. Kanis JA, Harvey N, Cooper C, Johansson H, Odén A, McCloskey E, et al. A systematic review of intervention thresholds based on FRAX: A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos. 2016;11,25.
26. Kanis JA, McCloskey E V., Johansson H, Oden A, Ström O, Borgström F. Development and use of FRAX® in osteoporosis. Osteoporos Int. 2010;21(Suppl 2):407–13.
27. Tosteson ANA, Iii LJM, Dawson-hughes B, Baim S, Favus J, Khosla S, et al. Cost-effective Osteoporosis Treatment Thresholds: The United States Perspective From the National Osteoporosis Foundation Guide Committee. Osteoporos Int. 2009;19(4):437–47.
28. Lewiecki EM, Cummings SR, Cosman F. Treat-to-target for osteoporosis: Is now the time? J Clin Endocrinol Metab. 2013;98(3):946–53.
29. Garber AJ. Treat-to-target trials: Uses, interpretation and review of concepts. Diabetes, Obes Metab. 2014;16(3):193–205.
30. Nogués X, Nolla JM, Casado E, Jódar E, Muñoz-Torres M, Quesada-Gómez JM, et al. Spanish consensus on treat to target for osteoporosis. Osteoporos Int. 2018;29(2):489–99.
31. McClung MR. Cancel the denosumab holiday. Osteoporos Int. 2016;27(5):1677–82.
32. Sosa Henríquez M, Gómez de Tejada Romero MJ, Malouf Sierra J. Clinical case to debate: therapeutic holidays: yes or no? Rev Osteoporos Metab Miner. 2014;6(2):63–9.
33. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus. J Bone Miner Res. 2015;30(1):3–23.
34. Ramírez L, López-Pintor RM, Casañas E, Arriba L de, Hernández G. New Non-Bisphosphonate Drugs that Produce Osteonecrosis of the Jaws. Oral Health Prev Dent. 2015;13(5):385–93.
35. Sosa-Henríquez M, Gómez de Tejada-Romero MJ, Bagán-Sebastián JV, Díaz-Curiel M, Díez-Pérez A, Jódar-Gimeno E, et al. Osteonecrosis of the jaw. Rev Osteoporos Metab Miner. 2009;1(1):53-61.
36. Zanchetta MB, Boailchuk J, Massari F, Silveira F, Bogado C, Zanchetta JR, et al. Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial. J Bone Miner Res. 2013;28(12):805–7.
37. Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res. 2011;26(3):530–7.